Retatrutide cut knee pain and 71 lbs in Phase 3 — here's the data.

What retatrutide is, and why TRIUMPH-4 matters

Retatrutide (Lilly code: LY3437943) is a once-weekly injectable peptide that activates three receptors at once: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and the glucagon receptor. The Phase 2 readout, published in The New England Journal of Medicine in 2023, reported a least-squares mean weight reduction of −24.2% at 48 weeks in the 12 mg group versus −2.1% in placebo — numbers that, at the time, made it the most potent investigational weight-loss molecule in humans by a meaningful margin [Jastreboff 2023]. We've covered the broader retatrutide and next-generation incretin story in adjacent pieces; this article is about a different question.

The TRIUMPH program is the Phase 3 trial series for retatrutide. Most of the program's attention has gone to TRIUMPH-1 and TRIUMPH-2 (obesity and obesity with type 2 diabetes, respectively). TRIUMPH-4 is the first Phase 3 readout for retatrutide in a different indication: knee osteoarthritis (OA) in adults with obesity. The trial randomized 445 participants 1:1:1 to retatrutide 9 mg, retatrutide 12 mg, or placebo, for 68 weeks, with co-primary endpoints of body weight change and change on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale [Lilly TRIUMPH-4 2026].

Two things make this trial interesting beyond the headline number. First, WOMAC is not a surrogate. It is a validated patient-reported outcome that anchors the regulatory framework for OA pain — a real endpoint, not a biomarker. Second, the comparator group received placebo plus lifestyle counseling, which means the trial is measuring the marginal effect of pharmacology on top of standard conservative care. That's the population sitting in orthopedic clinics right now: people too obese for a clean knee replacement outcome, too painful for physical therapy alone, and stuck.

What TRIUMPH-4 actually showed

The Lilly topline release reported that both retatrutide doses met all primary and key secondary endpoints. From a mean baseline weight of 112.7 kg (248.5 lbs) and mean baseline body-mass index (BMI) of 40.4 kg/m², the 12 mg group lost an average of −28.7% of body weight (−32.3 kg / −71.2 lbs) at 68 weeks. The 9 mg group lost an average of approximately −22.1%. Placebo lost roughly −2% with lifestyle counseling alone [Lilly TRIUMPH-4 2026].

The WOMAC pain numbers were proportionally striking. WOMAC pain is typically reported on a 0–100 normalized scale, with higher scores meaning worse pain. The 12 mg retatrutide group reported a mean reduction of approximately 4.5 points on the underlying 0-to-20 WOMAC pain subscale, equivalent to a −75.8% reduction relative to baseline. Placebo reduction on the same scale was meaningfully lower.

Responder analyses are where the clinical signal becomes harder to wave away. A 70% or greater reduction in WOMAC pain — a threshold most rheumatologists would call a clinically meaningful response — was achieved by 73.0% of patients on retatrutide 9 mg and 67.7% on retatrutide 12 mg, versus 26.2% on placebo. In a post-hoc analysis, 14.1% of patients on 9 mg and 12.0% on 12 mg were completely free of knee pain at week 68, compared with 4.2% on placebo [Lilly TRIUMPH-4 2026].

Secondary endpoints moved the way the broader retatrutide literature would predict. Non-HDL cholesterol fell. Triglycerides fell. High-sensitivity C-reactive protein (hsCRP), an aggregate measure of systemic inflammation, fell. Systolic blood pressure dropped by up to 14.0 mmHg in the 12 mg arm. SF-36 physical-function scores improved. Adverse events were dominated by gastrointestinal symptoms — nausea, diarrhea, constipation, vomiting, decreased appetite — which is the signature side-effect profile of the incretin class [Lilly TRIUMPH-4 2026].

TRIUMPH-4 isn't just a weight-loss trial with a knee questionnaire bolted on. The WOMAC effect is large enough, and the responder fraction high enough, that it reframes what "treating" knee OA with obesity can mean.

The numbers — weight and WOMAC pain, side by side

Comparison is the right move here, because the two existing reference points for "GLP-1-class drug for knee OA" are STEP 9 (semaglutide) and LOSEIT (liraglutide). The contrast is informative.

STEP 9 was the Phase 3 trial of subcutaneous semaglutide 2.4 mg in 407 adults with obesity and moderate knee OA, published in NEJM in late 2024. At 68 weeks, mean body weight change was −13.7% with semaglutide versus −3.2% with placebo. Mean change in WOMAC pain was −41.7 points (semaglutide) versus −27.5 points (placebo) on the 0–100 normalized scale, p<0.001 — a clinically meaningful but more modest separation than what TRIUMPH-4 produced [Bliddal 2024 STEP 9]. SF-36 physical-function gains favored semaglutide as well (+12.0 vs +6.5 points).

LOSEIT is the cautionary contrast. It tested liraglutide 3 mg daily versus placebo for 52 weeks in adults with overweight or obesity and knee OA. The liraglutide group lost a modest amount of weight (under 5%) and showed no greater knee-pain reduction than placebo at the 52-week mark [Gudbergsen LOSEIT 2021]. The most parsimonious reading: the joint-pain effect of an incretin-class drug scales with the magnitude of weight loss. Drugs that produce 2–4% weight loss don't shift the WOMAC curve; drugs that produce 13–29% weight loss do.

That observation matters, because retatrutide's pain reduction is proportionally larger than semaglutide's, and the weight loss is proportionally larger as well. The question of whether the extra pain signal is purely the marginal effect of more weight loss — or whether retatrutide is doing something else in the joint — is where the next section lives.

Mechanical vs anti-inflammatory: where does the pain effect come from?

The dominant assumption in the orthopedic literature, going back two decades, has been that obesity-related knee OA is fundamentally a loading problem. Cartilage wears down faster under chronic excess compression, alignment shifts as soft tissue accumulates, and pain scales with the load. Take the load off, and the joint settles.

The biomechanical math is real. Messier and colleagues, working at Wake Forest, reported that each pound of body weight lost translates to roughly a four-pound reduction in peak compressive force at the knee per step during normal walking [Messier 2005]. For someone who loses 71 lbs in TRIUMPH-4, the per-step load reduction is on the order of 280 lbs of compressive force. Over the thousands of steps a day a community-dwelling adult takes, that is not a marginal intervention. It is a mechanical reset.

The IDEA trial, run by the same Wake Forest group and published in JAMA in 2013, randomized 454 overweight or obese adults with knee OA to 18 months of intensive diet, intensive diet plus exercise, or exercise alone. The diet-plus-exercise arm produced the biggest improvements in pain, function, mobility, and quality of life — and peak knee compressive loads dropped by more than 200 N per step in the diet-loss arms versus exercise alone [Messier 2013 IDEA]. IDEA is the cleanest pre-pharmacology evidence that, in this population, weight loss does reduce the load and the pain.

But mechanical load is not the whole story, and the GLP-1-axis literature is the reason we know that. GLP-1 receptors are expressed in human chondrocytes and in synovial membrane tissue from osteoarthritic knees. Pre-clinical work — both cell-culture and in-vivo rodent models — has shown that GLP-1 receptor agonists bind GLP-1R, activate the cAMP / PKA pathway, and downstream inhibit NF-κB signaling. The net effect, repeatedly replicated, is reduced expression of pro-inflammatory cytokines including interleukin-1 beta (IL-1β), IL-6, tumor necrosis factor alpha (TNF-α), and high-mobility group box 1 (HMGB-1), alongside reduced expression of matrix metalloproteinases (MMP-3, MMP-13) and ADAMTS proteases that drive type II collagen and aggrecan breakdown [Chen 2022 GLP-1 OA] [Meurot Liraglutide 2022].

Translation: in a dish and in mice, GLP-1 receptor activation looks chondroprotective and synovium-calming, independent of weight loss. Whether that translates to humans at clinically relevant doses, and whether retatrutide's GIP and glucagon co-agonism amplifies or just rides along with the GLP-1 effect, is not yet known. The clinical signal that something non-mechanical may be happening is the hsCRP drop, the secondary inflammatory-marker movements, and the rapid pain improvements that often appear in the trial data before the full weight loss is realized.

The most honest read in 2025 is that the pain effect in TRIUMPH-4 is very likely a sum of three contributions: (1) a large mechanical decompression from weight loss, which the Messier and IDEA work predicts will produce real pain reduction on its own; (2) a systemic anti-inflammatory effect from incretin signaling, of which the hsCRP and triglyceride changes are downstream markers; and (3) a plausible local joint-tissue effect from GLP-1 receptor activation in chondrocytes and synovium, supported by pre-clinical data but not yet decomposed from the first two in any human trial. The fractional attribution is unknown. The total signal is large enough that the attribution question is mostly academic for the patient sitting in the orthopedic clinic.

Comparison to bariatric outcomes for knee OA

Bariatric surgery is the closest non-pharmacological reference point for this magnitude of weight loss. The literature here is observational but consistent. A systematic review of 13 studies including 3,837 patients reported significant improvements in knee pain, stiffness, and physical function across the majority of post-bariatric cohorts, with mean WOMAC pain reductions in the range typically required for clinical meaningfulness [Groen 2015 bariatric OA review]. Sleeve gastrectomy and Roux-en-Y gastric bypass cohorts produce weight loss in the 25–35% total body weight range at 12–24 months, which is the range TRIUMPH-4's 12 mg arm enters at 68 weeks.

The comparison cuts both ways. Bariatric surgery delivers comparable or greater weight loss but with surgical morbidity, slow recovery, and a population filter (patients who can tolerate the operative course and post-op nutrition). Retatrutide, at trial doses, delivers a similar order-of-magnitude weight loss without anesthesia or anatomical alteration — at the cost of indefinite weekly injections, gastrointestinal adverse events, the weight-regain question on discontinuation, and a class-specific concern about lean-mass preservation under aggressive caloric deficit. The two interventions are not equivalent. But they are now in the same conversation, and for a knee-OA patient with class II or III obesity, that's new.

The OARSI and ACR guideline updates over the past decade have made clear that weight loss is a guideline-level recommendation for knee OA in patients with overweight or obesity, with effect sizes scaling with the magnitude of loss. Until very recently, there was no pharmacological route to that magnitude of weight loss outside of surgery. STEP 9 opened the door. TRIUMPH-4 walked further in.

Who this matters for

The TRIUMPH-4 population is specific. Inclusion required obesity or overweight (mean BMI 40.4) plus a clinical and radiographic diagnosis of moderate knee OA, with at least moderate baseline pain. This is not a normal-BMI runner with patellofemoral irritation. This is a population frequently caught between three uncomfortable options:

• Continue conservative management — physical therapy, NSAIDs as needed, intra-articular hyaluronic acid or corticosteroid injections. Real but modest effects, and a meaningful fraction of patients deteriorate over the multi-year horizon.
• Pursue total knee arthroplasty (TKA) — definitive but with a higher complication rate at BMI > 40 and a non-trivial fraction of orthopedic practices recommending pre-surgical weight loss before scheduling. Recent literature and updated American College of Rheumatology / American Association of Hip and Knee Surgeons positions argue against absolute BMI thresholds for surgery, but in practice, access is patchier than the guidelines imply [ACR/AAHKS 2023].
• Try to lose the weight first — historically a low-yield path through lifestyle alone in this population. Bariatric surgery is effective but high-barrier.

Retatrutide, if it reaches the OA label, slots into this gap. It is not a replacement for joint replacement in someone with end-stage cartilage loss and bone-on-bone radiographic findings. It is plausibly a high-leverage option for the population with moderate OA, significant obesity, and a multi-year horizon between current symptoms and eventual surgical candidacy. For some of that population, TRIUMPH-4's data suggests retatrutide could meaningfully delay or recontextualize the surgical conversation.

Two adjacent uses are also worth flagging. First, pre-surgical optimization — using a pharmacological weight-loss bridge to bring a patient from BMI 42 to BMI 32 before TKA — is a use case where retatrutide's profile slots in naturally, though it has not yet been formally studied in that context. Second, for patients with contralateral knee or hip OA at risk of progression, weight loss of this magnitude is the most evidence-supported preventive intervention we have. The tirzepatide vs semaglutide conversation around weight-loss magnitude is the same conversation here, with retatrutide pushing the upper bound further.

What we still don't know

Several things need to be said clearly.

Topline release is not peer review. TRIUMPH-4's numbers are from a Lilly press release, not from a published trial manuscript with full safety tables, subgroup analyses, dropout accounting, and estimand sensitivity analyses. The Phase 2 retatrutide data eventually appeared in NEJM with substantially more detail than the topline announcement, and we expect the same for TRIUMPH-4. Until then, the headline numbers are real but the texture is not yet public.

Structural progression is not the same as pain. TRIUMPH-4 measured WOMAC pain and physical function. It did not report magnetic resonance imaging (MRI) cartilage thickness, joint space width on radiograph, or markers of cartilage turnover (CTX-II, COMP). A drug that reduces symptoms without altering disease progression is still useful. A drug that does both would be a more substantial claim. The pre-clinical data on GLP-1 axis chondroprotection is suggestive; the human structural data is not yet available.

Long-term durability is unknown. 68 weeks is long for a Phase 3 OA trial. It is not long for understanding what happens to weight, pain, and function over the multi-decade horizon of knee OA. The class precedent — see GLP-1 weight regain — is that discontinuation typically returns most patients to within a few kg of baseline body weight over 12–24 months. Whether OA pain rebounds in proportion is an open question; cartilage and joint biology may not respond as rapidly as adipose tissue does.

Lean mass and falls. Aggressive weight loss in older adults — especially those with limited baseline activity and existing knee OA — raises the question of lean-mass preservation and fall risk. Resistance training and adequate protein intake (1.2–1.6 g/kg of reference body weight) are mitigations that the recovery-pain hub covers in more depth. The trial data does not yet break down body-composition changes, hand-grip strength, or fall incidence in detail.

Cost, access, and insurance. Retatrutide is not yet approved by the U.S. Food and Drug Administration (FDA). When and if it is, coverage for an OA indication will be a separate fight from coverage for obesity. The current incretin-class access story is uneven enough that TRIUMPH-4's clinical promise does not automatically translate to clinical availability for the patients who would benefit most.

The triple-agonism question is unresolved. Retatrutide adds glucagon-receptor agonism to the GIP/GLP-1 combination that tirzepatide already covers. Glucagon-receptor activation drives hepatic glucose output and energy expenditure; in the obesity context it appears to amplify weight loss. Whether the glucagon arm adds anything specifically to the joint — anti-inflammatory, chondroprotective, or otherwise — is not established. The reference profile on retatrutide walks through the receptor pharmacology in more detail.

Bottom line

TRIUMPH-4 is the most consequential Phase 3 readout in the obesity-OA intersection to date. The numbers — up to 71.2 lbs of weight loss, a 75.8% reduction in WOMAC pain, and 1 in 8 patients completely pain-free at 68 weeks — are large enough to redraw the treatment map for adults with moderate knee OA and significant obesity. The mechanism is most likely a combination of substantial mechanical decompression of the joint, systemic anti-inflammatory effects from incretin signaling, and possibly direct GLP-1R-mediated effects on chondrocytes and synovium that the pre-clinical work keeps surfacing.

The honest caveats stack the way they always do for trial topline announcements. We do not yet have the published manuscript, the full safety profile, MRI structural endpoints, or the long-tail durability story. And retatrutide remains an investigational drug — not approved for obesity, not approved for OA, not on any pharmacy shelf as of publication of this article. What TRIUMPH-4 does establish is that the long-running question of "can we treat obesity-related OA pharmacologically before the orthopedic surgeon takes over?" now has a different default answer than it did a year ago.

If you are reading this with a family member or yourself in the target population, the actionable point is not "ask for retatrutide" — you cannot have it yet. It is to take the TRIUMPH-4 result as evidence that the weight-loss conversation, in the OA context, has become genuinely high-leverage in a way it wasn't a decade ago. Whatever route to weight loss is feasible for the specific patient — diet plus structured exercise, GLP-1 or GIP/GLP-1 dual agonists already approved, bariatric surgery, or eventually a triple agonist — the underlying biological story now strongly favors the weight-loss route over symptomatic-only management.